Novo Integrated Sciences

Novo Integrated Sciences operates a multidisciplinary healthcare ecosystem focused on decentralized delivery of non-catastrophic primary care through clinics, telemedicine technology, remote monitoring solutions, and over-the-counter preventative health products. The company emphasizes holistic patient-first approaches but does not have traditional clinical trial results as it primarily delivers services/products rather than prescription therapeutics.\n\nFinancially as of August 2024 they reported $8.3M in healthcare services revenue and $4.92M in product sales for the year ended August 31, with operations mainly in Canada.\n\nThe company has faced financial challenges but pursues non-dilutive financing to support growth initiatives.\n\nNo clinical pipeline or investigational drugs are disclosed.\n\nProducts include Terragenx micro-dosing iodine solution ("IoNovo Iodine") for all ages/lifestyles and ProDip dietary supplement pouches.\n\nTechnologies include telemedicine platforms such as "Novo Connect" app for enhanced patient/practitioner interaction.\n\nSubsidiaries provide consulting services globally; Clinical Consultants International focuses on hospital consulting.\n\nKey people include CEO Robert Mattacchione.\n\nHeadquarters are located in Bellevue, Washington.